Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics [electronic resource] /
Tao, Jianguo.editor.
Sotomayor, Eduardo.editor.
In the last decade, there has been a remarkable explosion of knowledge in hematologic cancer from basic molecular biology and pathology to clinical therapy. This has led to many new advance and insights in the understanding of pathobiology of malignant hematology. New knowledge of disease molecular pathology, cytogenetic, epigenetic and genomic alterations have provided new strategies to attack and eradicate tumor cells at molecular level and significantly impacted our current therapeutics for hematological malignancies. The recent and ongoing rapid expansion of knowledge in this area has become extensive, dynamic and diffuse over the literature and research publications. This has led to the need to capture and compile the new and current information about hematologic cancer with special emphasis on translation from molecular pathobiology to targeted therapeutics. In this book experts from around the world share their thoughts and knowledge about the pathobiology of hematologic cancer, as well as their view on current treatment approaches and future development in these malignant hematologic diseases. This book is well suited for hematology residents, fellows and hematology-oncology physicians, hematopathologist as well as basic research scientist in the area of hematologic malignancies. .
Description based upon print version of record.
Hematologic Cancers: From Molecular Pathobiologyto Targeted Therapeutics; Contents; B Cell Growth, Differentiation and Malignancies; Abstract; B Cell Development; B Cell Activation via the BCR; BCR Signal Transduction in B Cell Malignancies; B Cell Activation via Toll-Like Receptors (TLRs); TLRs in B Cell Malignancies; Transcription Factors Required for B Cell Differentiation and Their Roles in B Cell Cancer; Pax5 in B Cell Development; The Roles of Pax5 in B Cell Malignancies; BCL6 in B Cell Development; BCL6 in B Cell Malignancies; IRF4 in B Cell Differentiation; IRF4 in B Cell Malignancies
PRDM1 in Plasma Cell DifferentiationPRDM1/Blimp-1 and B Cell Malignancies; IRE-1-Mediated XBP-1 Activation in B Cell Differentiation; Crosstalk Between XBP-1 and Other Transcription Factors in B Cell Differentiation; IRE-1 and XBP-1 in B Cell Malignancies; Crucial Cell Survival and Growth Pathways That Contributes to B Cell Malignancies-The NF k B and mTOR Pathways; References; Follicular Lymphoma: Recent Advances; Introduction; Pathobiology of Follicular Lymphoma; Pathology of Follicular Lymphoma; Specific Variants of FL; Prognostic Factors in FL; Clinical Presentation and Diagnosis
Current Treatment StrategyReferences; Chronic Lymphocytic Leukemia: From Pathobiology to Targeted Therapy; Introduction; Chromosomal and Epigenetic Changes; Microenvironment; Targeting Microenvironments Created by CLL Cells; Aggressive CLL Is a Consequence of Constant B Cell Receptor Activation; Targeting B Cell Receptor Signaling for the Treatment of CLL; Expression of Toll-Like Receptors in Normal B Cells and CLL Cells; Targeting TLRs for the Treatment of CLL; Roles of Chaperone Proteins in the Development and Treatment of CLL; References
Genetic and Environmental Determinants in Multiple Myeloma: Implications for TherapyIntroduction; Progression of Multiple Myeloma; Genetic Contributions to Multiple Myeloma; Translocation (4; 14)(p16; q32) -MMSET/FGFR3; Translocation (6; 14) and t(11; 14)(q13; q32)-Cyclin D3 and Cyclin D1; Translocation (14; 16)(q32;  q23) and t(14; 20)(q32; q11) -c-MAF and MAFB; Hyperdiploidy and Trisomy; Loss of Tumor Suppressor Genes; Deletion of Chromosome 13; Deletion of Chromosome 17p; Chromosome 1 Aberrations; Secondary Mutations; Genome Sequencing; Gene Expression Profiling (GEP)
Therapeutic ImplicationsRisk Adapted Therapy; Novel Therapies in Myeloma Targeting the Genome; Targeting FGFR3; Targeting RAS; Targeting MYC; Non-genetic Contributions to Myeloma; Microenvironmental Contributions to Multiple Myeloma; The Bone Marrow Niche; The Bone Marrow Niche and Drug Resistance; Soluble Factors; Direct Cell Contact; A Complex Network of Survival Signals; Therapeutic Implications; Conclusion; References; EBV-Positive Diffuse Large B-Cell Lymphoma of the Elderly; Definitions; Initial Descriptions; Pathogenesis; Epstein Barr Virus Infection; Immunosenescence
Patterns of EBV Latency in EBV-Positive DLBCL of the Elderly
Includes bibliographical references and index.
In the last decade, there has been a remarkable explosion of knowledge in hematologic cancer from basic molecular biology and pathology to clinical therapy. This has led to many new advance and insights in the understanding of pathobiology of malignant hematology. New knowledge of disease molecular pathology, cytogenetic, epigenetic and genomic alterations have provided new strategies to attack and eradicate tumor cells at molecular level and significantly impacted our current therapeutics for hematological malignancies. The recent and ongoing rapid expansion of knowledge in this area has become extensive, dynamic and diffuse over the literature and research publications. This has led to the need to capture and compile the new and current information about hematologic cancer with special emphasis on translation from molecular pathobiology to targeted therapeutics. In this book experts from around the world share their thoughts and knowledge about the pathobiology of hematologic cancer, as well as their view on current treatment approaches and future development in these malignant hematologic diseases. This book is well suited for hematology residents, fellows and hematology-oncology physicians, hematopathologist as well as basic research scientist in the area of hematologic malignancies. .
Cancer research.
Hematology.
Laboratory medicine.
Molecular biology.
Apoptosis.
Cell biology.
Cancer Research.
Hematology.
Laboratory Medicine.
Molecular Medicine.
Apoptosis.
Cell Biology.